Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pay-for-delay

- PMLiVE

Indian generics companies poised for branded push

Report predicts manufacturing innovation will be harnessed for new patented products

- PMLiVE

Lundbeck losses deepen on EU fine

Pay-for-delay penalty contributes to operating loss of 506m Danish krone

- PMLiVE

Merck profit slides as generics continue to bite

Singulair, Maxalt, Cozaar and Clarinex sales all affected

- PMLiVE

Pfizer separates branded and generic divisions

Follows spin out of animal health and nutrition

- PMLiVE

UCB files Vimpat patent claims against 15 companies

Aurobindo, Glenmark, Mylan, Ranbaxy and Sandoz all face legal challenge over generic versions of UCB's epilepsy drug

- PMLiVE

Non-amyloid therapies emerging for Alzheimer’s at AAIC

AAIC meeting hears new clinical data from Lundbeck, Baxter, Chiesi and Takeda

- PMLiVE

European Commission hails progress on paediatric medicines

Says improvements made on both safety and research in Europe

- PMLiVE

Merck wins injunction against Januvia generics in India

Court blocks Aprica from launching copycat diabetes drug

- PMLiVE

Lundbeck to cut 50 jobs in Europe

Part of restructuring operations to cope with patent loss for Cipralex/ Lexapro

EU flag

EC fines pharma companies €146m for generic Celexa delay

Lundbeck, Alpharma, Merck KGaA, Generics UK, Arrow and Ranbaxy all hit

- PMLiVE

Pay-for-delay deals ‘sometimes violate antitrust law’

US Supreme Court rules on deals between pharma and generic drug companies

- PMLiVE

Pay-for-delay deals lead to inflated drug prices says study

Based on analysis of delayed market entry of generic Adderall XR in US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links